Repros Therapeutics Inc  

(Public, NASDAQ:RPRX)   Watch this stock  
Find more results for RPRX
8.43
-0.06 (-0.71%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.31 - 8.70
52 week 5.91 - 22.55
Open 8.52
Vol / Avg. 171,677.00/417,546.00
Mkt cap 204.65M
P/E     -
Div/yield     -
EPS -1.39
Shares 24.28M
Beta 1.26
Inst. own 67%
Jun 16, 2015
Repros Therapeutics Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 28, 2015
Repros Therapeutics Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
May 11, 2015
Q1 2015 Repros Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 16, 2015
Q4 2014 Repros Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -61.13% -52.90%
Return on average equity -64.81% -55.84%
Employees 28 -
CDP Score - -

Address

2408 Timberloch Pl Ste B7
THE WOODLANDS, TX 77380-1021
United States - Map
+1-281-7193400 (Phone)
+1-281-7193446 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Repros Therapeutics Inc. is a development-stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company�s product candidates include Androxal and Proellex. The Company�s Androxal is an oral therapy that normalizes testicular function, for the treatment of low testosterone due to secondary hypogonadism and Proellex is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. The Company�s primary product candidate, Androxal is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. The Company�s Proellex product candidate for female reproductive health is a chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis.

Officers and directors

Nola E. Masterson Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Joseph S. Podolski President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Katherine A. Anderson CPA Chief Financial Officer, Chief Accounting Officer, Secretary
Age: 56
Bio & Compensation  - Reuters
Jaye L. Thompson Ph.D. Senior Vice President - Clinical and Regulatory
Age: 48
Bio & Compensation  - Reuters
Ronald D. Wiehle Ph.D. Vice President - Research & Development
Age: 65
Bio & Compensation  - Reuters
Joachim F. Wernicke Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Michael Suesserman Director
Age: 49
Bio & Compensation  - Reuters
Daniel F. Cain Independent Director
Age: 68
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Saira Ramasastry Independent Director
Age: 38
Bio & Compensation  - Reuters
Michael G. Wyllie Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters